SANTEN PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1890-01-01
- Employees
- 3.7K
- Market Cap
- $4.5B
- Website
- http://www.santen.co.jp
A Pharmacokinetics (PK) Study in Healthy Adults
Early Phase 1
Completed
- Conditions
- Blepharoptosis
- Interventions
- Drug: STN1013800 ophthalmic solution
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT06911216
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
A Study in Chinese Patients With Acquired Blepharoptosis
Phase 3
Recruiting
- Conditions
- Blepharoptosis
- Interventions
- Drug: STN1013800 ophthalmic solutionDrug: STN1013800 ophthalmic solution Liquid Base, without STN1013800
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06683651
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
Phase 3
Recruiting
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 338
- Registration Number
- NCT06666855
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Beijing Tongren Hospital, Capital Medical University, Beijing, China
Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers
Phase 1
Completed
- Conditions
- Healthy Adult Males Volunteers
- Interventions
- Drug: STN1012600 ophthalmic solution 0.002%
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05905653
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan
A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Drug: STN1012600 ophthalmic solution 0.002%Drug: STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 131
- Registration Number
- NCT05503901
- Locations
- 🇯🇵
Kitanagoya Eye Clinic, Aichi, Japan
🇯🇵Miyake Eye Hospital, Aichi, Japan
🇯🇵Nagasaka Eye Clinic, Aichi, Japan
A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Drug: STN1012600 ophthalmic solution 0.002%
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 325
- Registration Number
- NCT05495061
- Locations
- 🇯🇵
Maeda Eye Clinic, Osaka, Japan
🇯🇵IMAI Eye Clinic, Yamanashi, Japan
🇯🇵Mitsuhashi Eye Clinic, Chiba, Japan
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Drug: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mLDrug: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 219
- Registration Number
- NCT03822559
- Locations
- 🇨🇳
Aier Eye Hospital Group Co., Ltd Changsha Aier Eye Hospital, Changsha, China
🇨🇳Eye & Ent Hospital of Fudan University, Shanghai, China
A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)
Phase 2
Completed
- Conditions
- Myopia
- Interventions
- Drug: DE-127 Ophthalmic Solution low doseDrug: Placebo Ophthalmic SolutionDrug: DE-127 Ophthalmic Solution medium doseDrug: DE-127 Ophthalmic Solution high dose
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT03329638
- Locations
- 🇸🇬
Singapore National Eye Centre, Singapore, Singapore
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
Phase 1
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Placebo ophthalmic solution and 3% DE-089 ophthalmic solution
- First Posted Date
- 2017-07-13
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03216096
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
Phase 3
Completed
- Conditions
- Open Angle Glaucoma or Ocular Hypertension
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 370
- Registration Number
- NCT02981446
© Copyright 2025. All Rights Reserved by MedPath